Brief: Treatment With Cytodyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration In Severely Ill Covid-19 Patients
02/04/2020 11:49
April 2 (Reuters) - Cytodyn Inc CYDY.PK :
* TREATMENT WITH CYTODYN'S LERONLIMAB INDICATES SIGNIFICANT
TREND
TOWARD IMMUNOLOGICAL RESTORATION IN SEVERELY ILL COVID-19
PATIENTS
Source text for Eikon: ID:nGNXc1Bd3M
Further company coverage: CYDY.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer